TY  - CONF
AU  - Jovanović, Marija
AU  - Ćulafić, Milica
AU  - Pejić, Nina
AU  - Štulić, Miloš
AU  - Kovačević, Milena
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Ćulafić, Đorđe
AU  - Vučićević, Katarina
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4531
AB  - Tacrolimus is an immunosuppressant used to prevent graft rejection after liver
transplantation. The narrow therapeutic range and great variability in pharmacokinetics
indicate the need for therapy individualization. The aim of the study was to develop and
validate the base pharmacokinetic model of tacrolimus using data collected during
therapeutic drug monitoring. The study included 29 liver transplant recipients followed up
at Clinic for Gastroenterology and Hepatology, Clinical Center of Serbia. Using the
NONMEM® program, we analyzed tacrolimus concentrations (Ctrough) measured in whole
blood (260). Pharmacokinetics have been described as one-compartment model with first-
order absorption and elimination. Internal validation was performed using graphical
assessment, bootstrap method and visual predictive check (VPC). Typical value of oral
clearance (CL/F) was 30.4 L/h, while value of oral volume of distribution was 5770 L. The
value of the absorption rate constant was fixed at 4.48 h-1 . Interindividual variability was
best described by the exponential model, and residual by the additive model. Interindividual
variability for CL/F was 38.2%. Individual predicted concentrations (IPRED) showed better
agreement with the measured values than population predicted values (PRED). Conditional
weighted residuals (CWRES vs PRED, CWRES vs TIME) were mostly between -2 and +2
standard deviations. The parameters obtained by bootstrap analysis do not deviate
significantly from the model. Median, 5th and 95th percentiles in the VPC method mostly
were within the simulated 95% confidence interval. The obtained population
pharmacokinetic model, after additional optimization, can be used for individualization of
the tacrolimus dosing regimen in the population of liver transplant recipients.
AB  - Takrolimus je imunosupresiv koji se primenjuje za prevenciju odbacivanja grafta
nakon transplantacije jetre. Uzak terapijski opseg i velika varijabilnost u farmakokinetici
ukazuju na neophodnost individualizacije terapije. Cilj istraživanja bio je razvoj i validacija
osnovnog farmakokinetičkog modela takrolimusa baziranog na podacima prikupljenim
tokom terapijskog praćenja leka. Studija je uključila 29 pacijenata sa transplantiranom
jetrom, praćenih na Klinici za gastroenterologiju i hepatologiju, Kliničkog centra Srbije.
Primenom NONMEM® programa analizirane su koncentracije takrolimusa izmerene u punoj
krvi (260), neposredno pre primene jutarnje doze (Ctrough). Farmakokinetika je opisana
jednoprostornim modelom sa resorpcijom i eliminacijom prvog reda. Interna validacija je
vršena primenom grafičke metode procene, metode umnožavanja podataka (bootstrap) i
vizuelne prediktivne provere (VPC). Procenjena tipična vrednost oralnog klirensa (CL/F)
iznosila je 30,4 L/h, dok je vrednost oralnog volumena distribucije bila 5770 L. Vrednost
konstante brzine resorpcije je fiksirana na 4,48 h-1 . Interindividualna varijabilnost je najbolje
opisana eksponencijalnim modelom, a rezidualna aditivnim modelom. Zabeležena je
interindividualna varijabilnost za CL/F od 38,2%. Predviđene individualne koncentracije
(IPRED) pokazuju bolje slaganje sa izmerenim vrednostima, nego populacione predviđene
vrednosti (PRED). Uslovni težinski reziduali (CWRES vs PRED, CWRES vs TIME) su većinom
raspoređeni između -2 i +2 standardne devijacije. Parametri dobijeni bootstrap analizom ne
odstupaju značajno od modela, dok su vrednosti medijane, 5. i 95. percentila u VPC metodi
uglavnom bile u okviru simuliranih 95% intervala pouzdanosti. Dobijeni populacioni
farmakokinetički model, može se nakon dodatne optimizacije, primeniti u svrhu
individualizacije režima doziranja takrolimusa u populaciji pacijenata sa transplantiranom
jetrom.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - A population pharmacokinetic model of tacrolimus in adult liver transplant recipients
T1  - Populacioni farmakokinetički model takrolimusa kod pacijenata sa transplantiranom jetrom
VL  - 72
IS  - 4 suplement
SP  - S298
EP  - S299
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4531
ER  - 

@conference{
author = "Jovanović, Marija and Ćulafić, Milica and Pejić, Nina and Štulić, Miloš and Kovačević, Milena and Vezmar-Kovačević, Sandra and Miljković, Branislava and Ćulafić, Đorđe and Vučićević, Katarina",
year = "2022",
abstract = "Tacrolimus is an immunosuppressant used to prevent graft rejection after liver
transplantation. The narrow therapeutic range and great variability in pharmacokinetics
indicate the need for therapy individualization. The aim of the study was to develop and
validate the base pharmacokinetic model of tacrolimus using data collected during
therapeutic drug monitoring. The study included 29 liver transplant recipients followed up
at Clinic for Gastroenterology and Hepatology, Clinical Center of Serbia. Using the
NONMEM® program, we analyzed tacrolimus concentrations (Ctrough) measured in whole
blood (260). Pharmacokinetics have been described as one-compartment model with first-
order absorption and elimination. Internal validation was performed using graphical
assessment, bootstrap method and visual predictive check (VPC). Typical value of oral
clearance (CL/F) was 30.4 L/h, while value of oral volume of distribution was 5770 L. The
value of the absorption rate constant was fixed at 4.48 h-1 . Interindividual variability was
best described by the exponential model, and residual by the additive model. Interindividual
variability for CL/F was 38.2%. Individual predicted concentrations (IPRED) showed better
agreement with the measured values than population predicted values (PRED). Conditional
weighted residuals (CWRES vs PRED, CWRES vs TIME) were mostly between -2 and +2
standard deviations. The parameters obtained by bootstrap analysis do not deviate
significantly from the model. Median, 5th and 95th percentiles in the VPC method mostly
were within the simulated 95% confidence interval. The obtained population
pharmacokinetic model, after additional optimization, can be used for individualization of
the tacrolimus dosing regimen in the population of liver transplant recipients., Takrolimus je imunosupresiv koji se primenjuje za prevenciju odbacivanja grafta
nakon transplantacije jetre. Uzak terapijski opseg i velika varijabilnost u farmakokinetici
ukazuju na neophodnost individualizacije terapije. Cilj istraživanja bio je razvoj i validacija
osnovnog farmakokinetičkog modela takrolimusa baziranog na podacima prikupljenim
tokom terapijskog praćenja leka. Studija je uključila 29 pacijenata sa transplantiranom
jetrom, praćenih na Klinici za gastroenterologiju i hepatologiju, Kliničkog centra Srbije.
Primenom NONMEM® programa analizirane su koncentracije takrolimusa izmerene u punoj
krvi (260), neposredno pre primene jutarnje doze (Ctrough). Farmakokinetika je opisana
jednoprostornim modelom sa resorpcijom i eliminacijom prvog reda. Interna validacija je
vršena primenom grafičke metode procene, metode umnožavanja podataka (bootstrap) i
vizuelne prediktivne provere (VPC). Procenjena tipična vrednost oralnog klirensa (CL/F)
iznosila je 30,4 L/h, dok je vrednost oralnog volumena distribucije bila 5770 L. Vrednost
konstante brzine resorpcije je fiksirana na 4,48 h-1 . Interindividualna varijabilnost je najbolje
opisana eksponencijalnim modelom, a rezidualna aditivnim modelom. Zabeležena je
interindividualna varijabilnost za CL/F od 38,2%. Predviđene individualne koncentracije
(IPRED) pokazuju bolje slaganje sa izmerenim vrednostima, nego populacione predviđene
vrednosti (PRED). Uslovni težinski reziduali (CWRES vs PRED, CWRES vs TIME) su većinom
raspoređeni između -2 i +2 standardne devijacije. Parametri dobijeni bootstrap analizom ne
odstupaju značajno od modela, dok su vrednosti medijane, 5. i 95. percentila u VPC metodi
uglavnom bile u okviru simuliranih 95% intervala pouzdanosti. Dobijeni populacioni
farmakokinetički model, može se nakon dodatne optimizacije, primeniti u svrhu
individualizacije režima doziranja takrolimusa u populaciji pacijenata sa transplantiranom
jetrom.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "A population pharmacokinetic model of tacrolimus in adult liver transplant recipients, Populacioni farmakokinetički model takrolimusa kod pacijenata sa transplantiranom jetrom",
volume = "72",
number = "4 suplement",
pages = "S298-S299",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4531"
}

Jovanović, M., Ćulafić, M., Pejić, N., Štulić, M., Kovačević, M., Vezmar-Kovačević, S., Miljković, B., Ćulafić, Đ.,& Vučićević, K.. (2022). A population pharmacokinetic model of tacrolimus in adult liver transplant recipients. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S298-S299.
https://hdl.handle.net/21.15107/rcub_farfar_4531

Jovanović M, Ćulafić M, Pejić N, Štulić M, Kovačević M, Vezmar-Kovačević S, Miljković B, Ćulafić Đ, Vučićević K. A population pharmacokinetic model of tacrolimus in adult liver transplant recipients. in Arhiv za farmaciju. 2022;72(4 suplement):S298-S299.
https://hdl.handle.net/21.15107/rcub_farfar_4531 .

Jovanović, Marija, Ćulafić, Milica, Pejić, Nina, Štulić, Miloš, Kovačević, Milena, Vezmar-Kovačević, Sandra, Miljković, Branislava, Ćulafić, Đorđe, Vučićević, Katarina, "A population pharmacokinetic model of tacrolimus in adult liver transplant recipients" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S298-S299,
https://hdl.handle.net/21.15107/rcub_farfar_4531 .

TY  - CONF
AU  - Jovanović, Marija
AU  - Ćulafić, Milica
AU  - Pejić, Nina
AU  - Štulić, Miloš
AU  - Kovačević, Milena
AU  - Vezmar-Kovačević, Sandra
AU  - Miljković, Branislava
AU  - Vučićević, Katarina
AU  - Ćulafić, Đorđe
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4395
AB  - Takrolimus je imunosupresiv koji se primenjuje za prevenciju odbacivanja grafta
nakon transplantacije jetre. Uzak terapijski opseg i velika varijabilnost u farmakokinetici
ukazuju na neophodnost individualizacije terapije. Cilj istraživanja bio je razvoj i validacija
osnovnog farmakokinetičkog modela takrolimusa baziranog na podacima prikupljenim
tokom terapijskog praćenja leka. Studija je uključila 29 pacijenata sa transplantiranom
jetrom, praćenih na Klinici za gastroenterologiju i hepatologiju, Kliničkog centra Srbije.
Primenom NONMEM® programa analizirane su koncentracije takrolimusa izmerene u punoj
krvi (260), neposredno pre primene jutarnje doze (Ctrough). Farmakokinetika je opisana
jednoprostornim modelom sa resorpcijom i eliminacijom prvog reda. Interna validacija je
vršena primenom grafičke metode procene, metode umnožavanja podataka (bootstrap) i
vizuelne prediktivne provere (VPC). Procenjena tipična vrednost oralnog klirensa (CL/F)
iznosila je 30,4 L/h, dok je vrednost oralnog volumena distribucije bila 5770 L. Vrednost
konstante brzine resorpcije je fiksirana na 4,48 h-1 . Interindividualna varijabilnost je najbolje
opisana eksponencijalnim modelom, a rezidualna aditivnim modelom. Zabeležena je
interindividualna varijabilnost za CL/F od 38,2%. Predviđene individualne koncentracije
(IPRED) pokazuju bolje slaganje sa izmerenim vrednostima, nego populacione predviđene
vrednosti (PRED). Uslovni težinski reziduali (CWRES vs PRED, CWRES vs TIME) su većinom
raspoređeni između -2 i +2 standardne devijacije. Parametri dobijeni bootstrap analizom ne
odstupaju značajno od modela, dok su vrednosti medijane, 5. i 95. percentila u VPC metodi
uglavnom bile u okviru simuliranih 95% intervala pouzdanosti. Dobijeni populacioni
farmakokinetički model, može se nakon dodatne optimizacije, primeniti u svrhu
individualizacije režima doziranja takrolimusa u populaciji pacijenata sa transplantiranom
jetrom.
AB  - Tacrolimus is an immunosuppressant used to prevent graft rejection after liver transplantation. The narrow therapeutic range and great variability in pharmacokinetics indicate the need for therapy individualization. The aim of the study was to develop and validate the base pharmacokinetic model of tacrolimus using data collected during therapeutic drug monitoring. The study included 29 liver transplant recipients followed up at Clinic for Gastroenterology and Hepatology, Clinical Center of Serbia. Using the NONMEM® program, we analyzed tacrolimus concentrations (Ctrough) measured in whole blood (260). Pharmacokinetics have been described as one-compartment model with first- order absorption and elimination. Internal validation was performed using graphical assessment, bootstrap method and visual predictive check (VPC). Typical value of oral clearance (CL/F) was 30.4 L/h, while value of oral volume of distribution was 5770 L. The value of the absorption rate constant was fixed at 4.48 h-1 . Interindividual variability was best described by the exponential model, and residual by the additive model. Interindividual variability for CL/F was 38.2%. Individual predicted concentrations (IPRED) showed better agreement with the measured values than population predicted values (PRED). Conditional weighted residuals (CWRES vs PRED, CWRES vs TIME) were mostly between -2 and +2 standard deviations. The parameters obtained by bootstrap analysis do not deviate significantly from the model. Median, 5th and 95th percentiles in the VPC method mostly were within the simulated 95% confidence interval. The obtained population pharmacokinetic model, after additional optimization, can be used for individualization of the tacrolimus dosing regimen in the population of liver transplant recipients.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Populacioni farmakokinetički model takrolimusa kod pacijenata sa transplantiranom jetrom
T1  - A population pharmacokinetic model of tacrolimus in adult liver transplant recipients
VL  - 72
IS  - 4 Suplement
SP  - S298
EP  - S299
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4395
ER  - 

@conference{
author = "Jovanović, Marija and Ćulafić, Milica and Pejić, Nina and Štulić, Miloš and Kovačević, Milena and Vezmar-Kovačević, Sandra and Miljković, Branislava and Vučićević, Katarina and Ćulafić, Đorđe",
year = "2022",
abstract = "Takrolimus je imunosupresiv koji se primenjuje za prevenciju odbacivanja grafta
nakon transplantacije jetre. Uzak terapijski opseg i velika varijabilnost u farmakokinetici
ukazuju na neophodnost individualizacije terapije. Cilj istraživanja bio je razvoj i validacija
osnovnog farmakokinetičkog modela takrolimusa baziranog na podacima prikupljenim
tokom terapijskog praćenja leka. Studija je uključila 29 pacijenata sa transplantiranom
jetrom, praćenih na Klinici za gastroenterologiju i hepatologiju, Kliničkog centra Srbije.
Primenom NONMEM® programa analizirane su koncentracije takrolimusa izmerene u punoj
krvi (260), neposredno pre primene jutarnje doze (Ctrough). Farmakokinetika je opisana
jednoprostornim modelom sa resorpcijom i eliminacijom prvog reda. Interna validacija je
vršena primenom grafičke metode procene, metode umnožavanja podataka (bootstrap) i
vizuelne prediktivne provere (VPC). Procenjena tipična vrednost oralnog klirensa (CL/F)
iznosila je 30,4 L/h, dok je vrednost oralnog volumena distribucije bila 5770 L. Vrednost
konstante brzine resorpcije je fiksirana na 4,48 h-1 . Interindividualna varijabilnost je najbolje
opisana eksponencijalnim modelom, a rezidualna aditivnim modelom. Zabeležena je
interindividualna varijabilnost za CL/F od 38,2%. Predviđene individualne koncentracije
(IPRED) pokazuju bolje slaganje sa izmerenim vrednostima, nego populacione predviđene
vrednosti (PRED). Uslovni težinski reziduali (CWRES vs PRED, CWRES vs TIME) su većinom
raspoređeni između -2 i +2 standardne devijacije. Parametri dobijeni bootstrap analizom ne
odstupaju značajno od modela, dok su vrednosti medijane, 5. i 95. percentila u VPC metodi
uglavnom bile u okviru simuliranih 95% intervala pouzdanosti. Dobijeni populacioni
farmakokinetički model, može se nakon dodatne optimizacije, primeniti u svrhu
individualizacije režima doziranja takrolimusa u populaciji pacijenata sa transplantiranom
jetrom., Tacrolimus is an immunosuppressant used to prevent graft rejection after liver transplantation. The narrow therapeutic range and great variability in pharmacokinetics indicate the need for therapy individualization. The aim of the study was to develop and validate the base pharmacokinetic model of tacrolimus using data collected during therapeutic drug monitoring. The study included 29 liver transplant recipients followed up at Clinic for Gastroenterology and Hepatology, Clinical Center of Serbia. Using the NONMEM® program, we analyzed tacrolimus concentrations (Ctrough) measured in whole blood (260). Pharmacokinetics have been described as one-compartment model with first- order absorption and elimination. Internal validation was performed using graphical assessment, bootstrap method and visual predictive check (VPC). Typical value of oral clearance (CL/F) was 30.4 L/h, while value of oral volume of distribution was 5770 L. The value of the absorption rate constant was fixed at 4.48 h-1 . Interindividual variability was best described by the exponential model, and residual by the additive model. Interindividual variability for CL/F was 38.2%. Individual predicted concentrations (IPRED) showed better agreement with the measured values than population predicted values (PRED). Conditional weighted residuals (CWRES vs PRED, CWRES vs TIME) were mostly between -2 and +2 standard deviations. The parameters obtained by bootstrap analysis do not deviate significantly from the model. Median, 5th and 95th percentiles in the VPC method mostly were within the simulated 95% confidence interval. The obtained population pharmacokinetic model, after additional optimization, can be used for individualization of the tacrolimus dosing regimen in the population of liver transplant recipients.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Populacioni farmakokinetički model takrolimusa kod pacijenata sa transplantiranom jetrom, A population pharmacokinetic model of tacrolimus in adult liver transplant recipients",
volume = "72",
number = "4 Suplement",
pages = "S298-S299",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4395"
}

Jovanović, M., Ćulafić, M., Pejić, N., Štulić, M., Kovačević, M., Vezmar-Kovačević, S., Miljković, B., Vučićević, K.,& Ćulafić, Đ.. (2022). Populacioni farmakokinetički model takrolimusa kod pacijenata sa transplantiranom jetrom. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 Suplement), S298-S299.
https://hdl.handle.net/21.15107/rcub_farfar_4395

Jovanović M, Ćulafić M, Pejić N, Štulić M, Kovačević M, Vezmar-Kovačević S, Miljković B, Vučićević K, Ćulafić Đ. Populacioni farmakokinetički model takrolimusa kod pacijenata sa transplantiranom jetrom. in Arhiv za farmaciju. 2022;72(4 Suplement):S298-S299.
https://hdl.handle.net/21.15107/rcub_farfar_4395 .

Jovanović, Marija, Ćulafić, Milica, Pejić, Nina, Štulić, Miloš, Kovačević, Milena, Vezmar-Kovačević, Sandra, Miljković, Branislava, Vučićević, Katarina, Ćulafić, Đorđe, "Populacioni farmakokinetički model takrolimusa kod pacijenata sa transplantiranom jetrom" in Arhiv za farmaciju, 72, no. 4 Suplement (2022):S298-S299,
https://hdl.handle.net/21.15107/rcub_farfar_4395 .

TY  - CONF
AU  - Ćulafić, Milica
AU  - Đorđević, J.
AU  - Stanković, Sanja
AU  - Štulić, Miloš
AU  - Pejić, Nina
AU  - Vezmar-Kovačević, Sandra
AU  - Oluić, Branislav
AU  - Miljković, Branislava
AU  - Ćulafić, Đorđe
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4337
PB  - Elsevier B.V.
C3  - Clinica Chimica Acta
T1  - Adverse drug reactions of tacrolimus after liver transplant - Our Experience
VL  - 530
IS  - Supplement 1
SP  - S448
EP  - S448
DO  - doi.org/10.1016/j.cca.2022.04.395
ER  - 

@conference{
author = "Ćulafić, Milica and Đorđević, J. and Stanković, Sanja and Štulić, Miloš and Pejić, Nina and Vezmar-Kovačević, Sandra and Oluić, Branislav and Miljković, Branislava and Ćulafić, Đorđe",
year = "2022",
publisher = "Elsevier B.V.",
journal = "Clinica Chimica Acta",
title = "Adverse drug reactions of tacrolimus after liver transplant - Our Experience",
volume = "530",
number = "Supplement 1",
pages = "S448-S448",
doi = "doi.org/10.1016/j.cca.2022.04.395"
}

Ćulafić, M., Đorđević, J., Stanković, S., Štulić, M., Pejić, N., Vezmar-Kovačević, S., Oluić, B., Miljković, B.,& Ćulafić, Đ.. (2022). Adverse drug reactions of tacrolimus after liver transplant - Our Experience. in Clinica Chimica Acta
Elsevier B.V.., 530(Supplement 1), S448-S448.
https://doi.org/doi.org/10.1016/j.cca.2022.04.395

Ćulafić M, Đorđević J, Stanković S, Štulić M, Pejić N, Vezmar-Kovačević S, Oluić B, Miljković B, Ćulafić Đ. Adverse drug reactions of tacrolimus after liver transplant - Our Experience. in Clinica Chimica Acta. 2022;530(Supplement 1):S448-S448.
doi:doi.org/10.1016/j.cca.2022.04.395 .

Ćulafić, Milica, Đorđević, J., Stanković, Sanja, Štulić, Miloš, Pejić, Nina, Vezmar-Kovačević, Sandra, Oluić, Branislav, Miljković, Branislava, Ćulafić, Đorđe, "Adverse drug reactions of tacrolimus after liver transplant - Our Experience" in Clinica Chimica Acta, 530, no. Supplement 1 (2022):S448-S448,
https://doi.org/doi.org/10.1016/j.cca.2022.04.395 . .

TY  - JOUR
AU  - Pejić, Nina
AU  - Stojković Lalošević, Milica
AU  - Štulić, Miloš
AU  - Ćulafić, Milica
AU  - Ćulafić, Đorđe
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4343
AB  - Introduction: COVID-19 is an infectious disease, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and there have been outbreaks worldwide. The presentation may include unspecific and mild symptoms, myalgia, headaches, high fever, dry cough, severe dyspnea and acute respiratory distress syndrome (ARDS). Case study: We present a rare case of microscopic polyangiitis (MPA) with interstitial lung disease and without renal involvement misdiagnosed as COVID-19. Conclusions: Differential diagnosis of COVID-19 is extremely important, and must be correctly identified in order to proceed with correct treatment.
PB  - Journal of Infection in Developing Countries
T2  - Journal of Infection in Developing Countries
T1  - Evaluating ground glass opacities (GGO) in the COVID-19 era. Do autoantibodies help?
VL  - 16
IS  - 9
SP  - 1530
EP  - 1532
DO  - 10.3855/jidc.16401
ER  - 

@article{
author = "Pejić, Nina and Stojković Lalošević, Milica and Štulić, Miloš and Ćulafić, Milica and Ćulafić, Đorđe",
year = "2022",
abstract = "Introduction: COVID-19 is an infectious disease, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and there have been outbreaks worldwide. The presentation may include unspecific and mild symptoms, myalgia, headaches, high fever, dry cough, severe dyspnea and acute respiratory distress syndrome (ARDS). Case study: We present a rare case of microscopic polyangiitis (MPA) with interstitial lung disease and without renal involvement misdiagnosed as COVID-19. Conclusions: Differential diagnosis of COVID-19 is extremely important, and must be correctly identified in order to proceed with correct treatment.",
publisher = "Journal of Infection in Developing Countries",
journal = "Journal of Infection in Developing Countries",
title = "Evaluating ground glass opacities (GGO) in the COVID-19 era. Do autoantibodies help?",
volume = "16",
number = "9",
pages = "1530-1532",
doi = "10.3855/jidc.16401"
}

Pejić, N., Stojković Lalošević, M., Štulić, M., Ćulafić, M.,& Ćulafić, Đ.. (2022). Evaluating ground glass opacities (GGO) in the COVID-19 era. Do autoantibodies help?. in Journal of Infection in Developing Countries
Journal of Infection in Developing Countries., 16(9), 1530-1532.
https://doi.org/10.3855/jidc.16401

Pejić N, Stojković Lalošević M, Štulić M, Ćulafić M, Ćulafić Đ. Evaluating ground glass opacities (GGO) in the COVID-19 era. Do autoantibodies help?. in Journal of Infection in Developing Countries. 2022;16(9):1530-1532.
doi:10.3855/jidc.16401 .

Pejić, Nina, Stojković Lalošević, Milica, Štulić, Miloš, Ćulafić, Milica, Ćulafić, Đorđe, "Evaluating ground glass opacities (GGO) in the COVID-19 era. Do autoantibodies help?" in Journal of Infection in Developing Countries, 16, no. 9 (2022):1530-1532,
https://doi.org/10.3855/jidc.16401 . .